Clinical Chemistry Analyzers Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents), By Test (BMP, Electrolyte Panel, Liver Panel, Lipid Profile), By End Use, And Segment Forecasts, 2022 - 2029

Report Overview

The global clinical chemistry analyzers market accounted for USD 16 billion in 2021 and is expected to grow at a CAGR of 4.7% from 2022 to 2029. The increasing prevalence of chronic diseases, such as diabetes, is predicted to be one of the high impact rendering drivers of this market. This subsequent increase in disease prevalence has triggered companies to produce advanced analyzers at a large scale, to aid in diagnosis. Consequently, the high need for chemistry analyzers led to unprecedented growth in new market entrants, resulting in high competition.

The technological innovations in clinical chemistry analyzers have led to early disease detection and specialized diagnosis in the areas of oncology, gynecology, & endocrinology and enabled testing on a larger scale. The advancements comprise advanced modeling & parameter estimation, better resolution, improved pattern recognition, computer-assisted interpretation, and artificial intelligence.

U.S. clinical chemistry analyzers market, by test, 2017 - 2029 (USD Million)

The benefits of the above-mentioned advancements and automated analyzers are automatic data acquisition, greater process control allowing real-time automation, efficient parameter monitoring, and automatic variable adjustment. These tools also offer analysis of a wide range of samples and facilitate immediate generation of results, reflecting their potential applications in the intensive care unit, outpatient clinics, and emergency as well as surgical wards in the future. These benefits are estimated to drive physician preference for these analyzers, thus creating high potential opportunities for growth during the forecast period.

Product Insights

Reagents accounted for the largest share in the product segment in 2015. The substantial share is predicted to be a consequence of a wide array of reagents present in the market, catering to different requirements of clinicians. These reagents predominantly include enzymes, substrates, specific proteins, electrolytes, lipids, and others, which are imperative to obtain accurate results in analytical procedures.

In addition, reagents are believed to be highly cost-efficient, possess optimum sensitivity, linearity, and precision, which thereby, ensures minimized performance variation. The aforementioned benefits are predicted to be highly responsible for encouraging clinicians to use reagents for accurate diagnosis.

Global clinical chemistry analyzers market share, by product, 2016

Test Insights

Basic MetabolicPanel (BMP) held a dominant share of the test segment in 2015, as a consequence of growing prevalence of lifestyle-induced diseases, such as obesity and other metabolic abnormalities. Rising importance of and awareness regarding point-of-care testing is also one of the key contributing factors toward the segment share. BMP comprises a set of tests that provide clinical information pertaining to problems caused by a chemical imbalance in the body to the medical examiners.

The associated benefits with this test have resulted in the high acceptance of the same, thereby widening the segment share over the years. Moreover, BMP is increasingly being used and accepted in a wide array of applications, such as in newborn screening, which facilitates early detection of congenital genetic as well as metabolic disorders. According to a research paper published in NCBI, it possesses the ability to detect 30 inherited metabolic disorders in a single dried filter paper blood spot.

End-use Insights

Hospitals dominated the end-use segment in 2016, owing to the high patient volume, frequent readmissions, and large sample volumes. Moreover, supportive infrastructure facilitates successful diagnostic procedures, thus, resulting in a higher share of hospitals. The increasing number of government initiatives aimed at promoting efficient diagnostic facilities to generate quick results and improve overall efficiency also serves as key contributing factors to the substantial share of the segment.

In addition, in the current scenario, hospitals are increasingly inclined toward acquiring fully automated systems with built-in quality-assurance capabilities, possessing the ability to process a large number of samples. These factors are estimated to exert positive influence on segment growth.

Regional Insights

In 2016, North America held the substantial share of the clinical chemistry analyzers market. The supportive government initiatives and high implementation of practice guidelines released by healthcare organizations present across this region are some of the key factors responsible for the high share registered by this region.

Due to increase in outsourcing of manufacture of these analyzers to Asia Pacific countries, such as India and China, this region is anticipated to grow at an exponential rate during the forecast period. Furthermore, high R&D investment by the global players and presence of unexplored opportunities in this region serve as high growth rendering drivers.

Clinical Chemistry Analyzers Market Share Insights

Some of the key market participants are F.Hoffmann La Roche; Thermo Fisher Scientific, Inc.; Johnson & Johnson; and Siemens AG. The aforementioned companies are extensively undertaking new and advanced product development activities, collaborative strategies, and mergers & acquisitions, leading to significant growth in this sector.

For instance, in January 2017, Roche launched cobas m 511, integrated hematology analyzer. This product was made available in many countries following the European approval system (CE mark). This product was launched to expand its hematology testing capabilities.

Recent Developments

• In March 2023, world scientific leader Thermo Fisher Scientific Inc. announced the completion of acquiring “The Binding Site Group”, the world's leading specialty diagnostics company. Binding Site expands the existing portfolio of specialty diagnostics by adding groundbreaking innovations in diagnostics and multiple myeloma surveillance. 

• In October 2022, Roche launched the PRAME (EPR20330) antibody to detect PRAME protein expression in patients who may have melanoma. Understanding PRAME protein expression will help make more informed clinical decisions and may improve patient outcomes.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2017 to 2029. For the purpose of this study, Grand View Research has segmented the global clinical chemistry analyzers market on the basis of product, test, end-use, and region:

• Product Outlook (Revenue, USD Million, 2017 - 2029)

  • Analyzers

    • Small

    • Medium

    • Large

    • Very Large

  • Reagents

    • Calibrators

    • Controls

    • Standards

    • Others

  • Others

• Test Outlook (Revenue, USD Million, 2017 - 2029)

  • Basic Metabolic Panel

  • Electrolyte Panel

  • Liver Panel

  • Lipid Profile

  • Renal Profile

  • Thyroid Function Panel

  • Specialty Chemical Tests

• End-use Outlook (Revenue, USD Million, 2017 - 2029)

  • Hospitals

  • Academic Research Centers

  • Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2017 - 2029)

  • North America

    • The U.S

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • The Middle East and Africa

    • South Africa